A comparative study of related outcomes of Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (SCT)

Trial Profile

A comparative study of related outcomes of Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (SCT)

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Melphalan
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top